The management of advanced Stage IV non-small cell lung cancer (NSCLC) has seen remarkable progress over the past decade, with significant advancements in treatment options. To ensure that clinical practice remains aligned with the latest research and evidence, the American Society of Clinical Oncology (ASCO) has established a series of Living Guidelines for NSCLC. These guidelines are continuously updated to incorporate emerging data. Similarly, the National Comprehensive Cancer Network (NCCN) regularly revises its guidelines, maintaining a dynamic and evidence-driven approach to incorporate the latest advancements in the field. Both guidelines are based on systematic literature reviews and are evaluated by expert panels to ensure that they reflect current scientific understanding.
In this edition of our Guidelines Side-by-Side, we provide a detailed comparison of the clinical practice guidelines put forth by ASCO and NCCN for NSCLC management. Through a thorough analysis of these guidelines, we aim to equip healthcare professionals with evidence-based insights and best practices, facilitating optimal patient care and ultimately improving outcomes for individuals diagnosed with advanced NSCLC.
Titles of Comparison:
| Titles | NCCN Guidelines for Non-Small Cell Lung Cancer (Version 3.2025) | ASCO Living Guideline for Stage IV Non-Small Cell Lung Cancer Without Driver Alterations (Version 2024.3) |
|---|---|---|
| Society | National Comprehensive Cancer Network (NCCN) | American Society of Clinical Oncology (ASCO) |
| Publication Date | January 14, 2025 | February 27, 2025 |
| Objective | To provide evidence-based, expert consensus-driven treatment recommendations for all stages of non-small cell lung cancer (NSCLC). | To provide current evidence-based treatment recommendations for Stage IV NSCLC without driver alterations. |
| Target Population | Patients with all stages of non-small cell lung cancer (NSCLC), including early-stage, locally advanced, and metastatic disease. | Patients with Stage IV NSCLC without driver alterations. |
| Methodology | Expert consensus, systematic review of available literature, and updated regularly. | Living guideline updated as new evidence becomes available, based on systematic review of current evidence. |
| Graded Strength of Recommendations | Yes | Yes |
| Graded Level of Evidence | Yes | Yes |
| Systematic Review Conducted | Yes | Yes |
| Literature Review Conducted | Yes | Yes |
| COIs & Funding Source(s) Disclosed | Yes | Yes |
| Full-text | NCCN Guidelines for Non-Small Cell Lung Cancer | ASCO Living Guideline for Stage IV Non-Small Cell Lung Cancer Without Driver Alterations (Version 2024.3) |
| Summary | N/A | Summary |
First-Line and Second-Line Treatments for Advanced NSCLC
| Treatment | NCCN Guideline | ASCO Living Guideline |
|---|---|---|
| First-Line Treatment | ||
| Immunotherapy (Single-Agent) | - Pembrolizumab (for PD-L1 ≥50%) - Atezolizumab (for PD-L1 ≥50%) - Nivolumab (for PD-L1 ≥50%) | - Pembrolizumab (for PD-L1 ≥50%) - Atezolizumab (for PD-L1 ≥50%) - Nivolumab (for PD-L1 ≥50%) |
| Chemotherapy + Immunotherapy | - Pembrolizumab + chemotherapy (for PD-L1 ≥1%) - Atezolizumab + chemotherapy (for PD-L1 ≥1%) - Nivolumab + chemotherapy (for PD-L1 ≥1%) | - Pembrolizumab + chemotherapy (for PD-L1 ≥1%) - Atezolizumab + chemotherapy (for PD-L1 ≥1%) - Nivolumab + chemotherapy (for PD-L1 ≥1%) |
| Chemotherapy Alone | - Platinum-based chemotherapy(e.g., Carboplatin or Cisplatin with Pemetrexed, Paclitaxel, or Docetaxel) | - Platinum-based chemotherapy(e.g., Carboplatin or Cisplatin with Pemetrexed, Paclitaxel, or Docetaxel) |
| Considerations for Elderly/Frail Patients | - Use single-agent chemotherapy (e.g., Pemetrexed or Gemcitabine) for frail or elderly patients. - Avoid combinations for frail patients. | - Use single-agent chemotherapy (e.g., Pemetrexed or Gemcitabine) for frail or elderly patients. - Consider performance status in therapy choice. |
| Second-Line Treatment | ||
| Immunotherapy (Single-Agent) | - Pembrolizumab - Nivolumab - Atezolizumab (after progression on first-line therapy, if no contraindication) | - Pembrolizumab- Nivolumab - Atezolizumab (after progression on first-line therapy) |
| Chemotherapy | - Docetaxel - Pemetrexed (for non-squamous histology) - Vinorelbine (for squamous histology) | - Docetaxel - Pemetrexed (for non-squamous histology) - Vinorelbine (for squamous histology) |
| Chemotherapy + Immunotherapy | - Nivolumab + chemotherapy - Pembrolizumab + chemotherapy (considered for patients after progression) | - Nivolumab + chemotherapy - Pembrolizumab + chemotherapy (considered for patients after progression) |
| Clinical Trial Consideration | - Strongly recommended for patients who are not candidates for standard therapies or for progression after second-line treatment. | - Emphasized for patients after progression on standard therapies. - Consider clinical trials as a treatment option. |
| Treatment for PD-L1 Negative Patients | - Platinum-based chemotherapy(e.g., Carboplatin/Pemetrexed, Cisplatin/Pemetrexed, or Paclitaxel) | - Platinum-based chemotherapy(e.g., Carboplatin/Pemetrexed, Cisplatin/Pemetrexed, or Paclitaxel) |
| Performance Status Considerations | - For patients with ECOG PS 2 or higher, consider more aggressive chemotherapy combinations or single-agent therapy. - Immunotherapy is generally avoided in patients with significantly impaired performance status. | - ECOG PS 2 or higher: Emphasis on single-agent chemotherapy or palliative care. - Immunotherapy should be considered based on PS. |
Key Takeaways
First-Line Therapy:
- Both the NCCN and ASCO guidelines emphasize the use of immunotherapy as a first-line treatment for patients with PD-L1 ≥50%, including agents like Pembrolizumab, Nivolumab, and Atezolizumab.
- Both guidelines also recommend chemotherapy in combination with immunotherapy for patients with PD-L1 ≥1%. Regimens such as Pembrolizumab + chemotherapy and Nivolumab + chemotherapy are included in the first-line treatment options.
- For patients with PD-L1-negative tumors, both guidelines suggest platinum-based chemotherapy as a primary treatment (e.g., Cisplatin/Pemetrexed or Carboplatin/Pemetrexed).
Second-Line Therapy:
- In the second-line setting, both guidelines recommend Pembrolizumab, Nivolumab, and Atezolizumab after progression on first-line therapy.
- Chemotherapy options in both guidelines include Docetaxel, Pemetrexed, and Vinorelbine, with the choice often depending on histology and performance status.
- Both guidelines consider combination therapy with immunotherapy + chemotherapy after progression on first-line therapy, although this is individualized based on patient-specific factors.
Performance Status and Elderly/Frail Patients:
- Both guidelines recommend adjusting treatment based on performance status. For elderly or frail patients, the treatment approach typically involves single-agent chemotherapy.
- Immunotherapy is generally avoided in patients with severely impaired performance status (e.g., ECOG PS 3 or 4), and the focus shifts to optimizing quality of life in such cases.
Clinical Trials:
- Both guidelines strongly encourage the consideration of clinical trials for patients who have progressed after standard therapies. ASCO places a stronger emphasis on clinical trial participation as part of the treatment strategy, especially in later lines of therapy.
Differences in Emphasis:
- ASCO places greater emphasis on clinical trial enrollment, particularly for patients with Stage IV NSCLC after progression on standard therapies.
- NCCN offers a broader range of therapy options for each line of treatment and places less emphasis on clinical trials compared to ASCO.
In conclusion, both the NCCN and ASCO guidelines offer comprehensive, evidence-based recommendations for the management of Stage IV non-small cell lung cancer (NSCLC) without driver alterations, but with some key differences in focus and approach. While both guidelines emphasize the role of immunotherapy and chemotherapy in first- and second-line treatments, ASCO's Living Guidelines place a stronger emphasis on clinical trials as a critical component of treatment, especially for patients who have exhausted standard therapies. On the other hand, NCCN provides a more extensive array of treatment options and allows for broader flexibility in choosing therapies based on individual patient characteristics. Ultimately, these guidelines serve as essential tools for healthcare professionals to make informed, evidence-based decisions tailored to each patient's unique clinical situation, improving the potential for better outcomes in the management of advanced NSCLC.
Make sure to sign up for guideline alerts to stay up to date on all future side-by-side blogs and let us know if there is a topic you’d like to see compared on our next article!
Copyright © 2025 Guideline Central, All Rights Reserved.